Related Experiment Video

Updated: Jan 6, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

489

Are We Aware that Hyperphosphatemia Affects Mortality and Morbidity as much as Hypophosphatemia in Pediatric

Yılmaz Akbaş1, Alper Koker2, Nilgün Erkek3

  • 1Hatay State Hospital, Department of Pediatrics, Hatay, Turkey.

Pediatric Endocrinology Reviews : PER
|October 11, 2019
PubMed

Insights

Hyperphosphatemia, like hypophosphatemia, significantly increases mortality and morbidity in pediatric intensive care patients. Elevated phosphorus levels on admission correlate with higher PELOD scores, indicating severe illness.

Area of Science:

  • Pediatric Intensive Care Medicine
  • Critical Care Nephrology
  • Pediatric Critical Illness

Background:

  • Hypophosphatemia is a known risk factor for adverse outcomes in pediatric intensive care.
  • Previous studies have focused on hypophosphatemia's impact on pediatric intensive care unit (PICU) patients.
  • The impact of hyperphosphatemia on PICU patient outcomes remains less understood compared to hypophosphatemia.

Purpose of the Study:

  • To investigate whether hyperphosphatemia affects morbidity and mortality in pediatric intensive care patients to a similar extent as hypophosphatemia.
  • To compare the impact of hyperphosphatemia and hypophosphatemia on pediatric intensive care outcomes.

Main Methods:

  • Retrospective data collection from pediatric intensive care unit patients.
  • Recording of patient demographics, admission diagnoses, and underlying conditions.
  • Monitoring of serum phosphorus levels on admission and during the first 10 days.
  • Documentation of mechanical ventilation duration, length of stay, and patient disposition.
  • Calculation of Pediatric Risk of Mortality (PRISM) and Pediatric Logistic Organ Dysfunction (PELOD) scores within 24 hours of admission.

Main Results:

  • Both hypophosphatemia and hyperphosphatemia were associated with significantly higher mortality rates compared to normophosphatemia.
  • The highest mortality was observed in patients with hyperphosphatemia on days 5-10.
  • Pediatric Logistic Organ Dysfunction (PELOD) scores were significantly higher in patients with hyperphosphatemia upon admission.

Conclusions:

  • Hyperphosphatemia poses a significant risk to pediatric intensive care unit patients, comparable to hypophosphatemia.
  • Hyperphosphatemia on admission is linked to increased severity of illness, as indicated by higher PELOD scores.
  • Both hypophosphatemia and hyperphosphatemia are critical factors that require attention in pediatric intensive care settings.
Abstract

Keywords:
HyperphosphatemiaHypophosphatemiaMortalityPELODPediatric intensive care

More Related Videos

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

2.3K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
227
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
514
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
163
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
311
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
184
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
210